IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VENETIS, KONSTANTINOS
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.262
AS - Asia 5.120
NA - Nord America 3.720
SA - Sud America 568
AF - Africa 154
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.871
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.500
DE - Germania 2.257
CN - Cina 2.099
SG - Singapore 1.199
IT - Italia 1.174
BR - Brasile 407
HK - Hong Kong 338
GB - Regno Unito 325
IN - India 271
BD - Bangladesh 270
RU - Federazione Russa 235
VN - Vietnam 232
NL - Olanda 222
FR - Francia 211
SE - Svezia 180
ES - Italia 173
JP - Giappone 113
CA - Canada 109
ID - Indonesia 106
TR - Turchia 96
IE - Irlanda 87
FI - Finlandia 80
KR - Corea 75
MX - Messico 75
TW - Taiwan 52
IR - Iran 50
CO - Colombia 47
PL - Polonia 47
AU - Australia 42
AT - Austria 36
PT - Portogallo 33
EG - Egitto 32
AR - Argentina 30
CH - Svizzera 30
BE - Belgio 28
IQ - Iraq 27
PH - Filippine 27
ZA - Sudafrica 26
IL - Israele 25
SA - Arabia Saudita 25
TH - Thailandia 25
PE - Perù 21
GH - Ghana 18
PK - Pakistan 18
RO - Romania 18
GR - Grecia 17
LT - Lituania 17
CI - Costa d'Avorio 16
CL - Cile 16
EC - Ecuador 16
AE - Emirati Arabi Uniti 15
MY - Malesia 14
UA - Ucraina 14
DK - Danimarca 12
KE - Kenya 12
MA - Marocco 12
VE - Venezuela 11
ET - Etiopia 9
NO - Norvegia 9
UY - Uruguay 9
RS - Serbia 8
BG - Bulgaria 7
HN - Honduras 7
HU - Ungheria 7
LU - Lussemburgo 7
PY - Paraguay 7
CR - Costa Rica 6
DZ - Algeria 6
GT - Guatemala 6
NG - Nigeria 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
JO - Giordania 5
PA - Panama 5
SC - Seychelles 5
UZ - Uzbekistan 5
AL - Albania 4
BO - Bolivia 4
EE - Estonia 4
GE - Georgia 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
TT - Trinidad e Tobago 4
HR - Croazia 3
LB - Libano 3
LK - Sri Lanka 3
MO - Macao, regione amministrativa speciale della Cina 3
NZ - Nuova Zelanda 3
SV - El Salvador 3
AM - Armenia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CY - Cipro 2
DO - Repubblica Dominicana 2
KG - Kirghizistan 2
KW - Kuwait 2
LV - Lettonia 2
NP - Nepal 2
OM - Oman 2
Totale 14.858
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.039
Singapore 654
Dallas 564
Ashburn 474
Hong Kong 264
Milan 256
San Jose 233
Hefei 203
Beijing 199
Chandler 169
Council Bluffs 169
Southend 150
Los Angeles 143
Santa Clara 124
Shanghai 124
New York 101
Guangzhou 100
Dublin 87
Fairfield 84
Bengaluru 79
Ho Chi Minh City 70
Jakarta 65
Lauterbourg 65
Hanoi 64
Istanbul 63
Rome 63
Boardman 60
Moscow 59
São Paulo 56
Shenzhen 52
Nanjing 51
Buffalo 48
Zhengzhou 48
Tokyo 47
Turin 43
Helsinki 42
Princeton 42
Munich 41
Seattle 41
Wilmington 41
Chicago 40
Seoul 40
Chengdu 33
Naples 33
The Dalles 32
Toronto 32
Nuremberg 31
Amsterdam 30
Houston 30
Woodbridge 30
London 29
Ann Arbor 28
Hangzhou 28
Vienna 27
Wuhan 27
Erechim 26
Berlin 24
Cambridge 24
Hyderabad 24
Shenyang 24
Cangzhou 23
Madrid 23
Fuzhou 22
Phoenix 22
Des Moines 21
Lappeenranta 21
Florence 20
Atlanta 19
Bogotá 19
Bologna 19
Gainesville 19
Paris 19
Changsha 18
Jinan 18
Lima 18
Warsaw 18
Chongqing 17
Tianjin 17
Abidjan 16
Huntley 16
Mexico City 16
Orem 16
Bangkok 15
Columbus 15
San Diego 15
Sydney 15
Taipei 15
Washington 15
Accra 14
Athens 14
Barcelona 14
Bergamo 14
Cairo 14
Manchester 14
Palermo 14
Ankara 13
Brussels 13
Chennai 13
Düsseldorf 13
Genoa 13
Totale 8.539
Salva come PNG Salva come JPEG
Nome #
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress 2.661
Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies 517
BREAST CANCER DURING PREGNANCY AS A SPECIAL TYPE OF EARLY-ONSET BREAST CANCER: INSIGHTS INTO THE TUMOR MICROENVIRONMENT AND IMMUNE TRANSCRIPTOME 347
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer 334
Computational pathology to improve biomarker testing in breast cancer: how close are we? 323
PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer 319
Targeting immune-related biological processes in solid tumors : we do need biomarkers 309
Pten alterations and their role in cancer management: Are we making headway on precision medicine? 293
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 283
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology 262
Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema 257
Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages 256
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 251
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 246
Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study 244
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 233
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 225
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 223
Mismatch repair-deficient hormone receptor-positive breast cancers : Biology and pathological characterization 222
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial 220
Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study 219
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients 217
Mismatch Repair Status Characterization in Oncologic Pathology : Taking Stock of the Real-World Possibilities 216
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 215
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 215
Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling 211
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 202
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 202
Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles 195
In-house homologous recombination deficiency testing in ovarian cancer: A multi-institutional Italian pilot study 194
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers 193
Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers 179
Low-risk triple-negative breast cancers: Clinico-pathological and molecular features 179
Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing 176
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis 173
Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients’ Quality of Life 173
Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies 170
Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms : A Pilot Randomized Clinical Study 167
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 166
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 164
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods 158
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis 157
Trop-2 as an Actionable Biomarker in Breast Cancer 154
HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes 154
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 152
Letter to the editor regarding the article “pregnancy-associated breast cancer: a multicenter study comparing clinicopathological factors, diagnosis, and treatment outcomes with non-pregnant patients” 148
The molecular landscape of breast mucoepidermoid carcinoma 144
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores 143
Spatially Resolved Molecular Approaches for the Characterisation of Non-Invasive Follicular Tumours with Papillary-like Features (NIFTPs) 137
Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing 136
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test 135
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy 131
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 129
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence 128
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 125
Exercise therapy to reduce breast cancer fatigue: Results from the EXPECT study 118
Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer 117
Biomarkers for precision immunotherapy in the metastatic setting : hope or reality? 108
ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality 102
Investigating the Pathogenicity of Uncommon KRAS Mutations and Their Association with Clinicopathologic Characteristics in Patients with Colorectal Cancer 99
Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances 94
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer 92
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing 88
Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients 86
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience 80
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 80
Improving HER2 testing reproducibility in HER2-low breast cancer 51
Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients 49
Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models 13
Artificial Intelligence in Thyroid Cytopathology: Diagnostic and Technical Insights 10
PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs 10
Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer 9
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study 6
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study 5
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209] 1
Totale 15.200
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.402
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202143 0 0 0 0 0 0 0 0 0 0 0 43
2021/2022515 58 28 21 33 39 39 39 33 90 43 21 71
2022/2023671 62 57 47 69 46 110 22 44 80 6 47 81
2023/20243.037 112 95 123 147 248 211 413 379 228 331 381 369
2024/20254.234 375 464 399 411 266 253 164 352 296 372 321 561
2025/20266.219 656 840 737 526 436 335 591 294 525 390 677 212
Totale 15.200